• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

缺氧通过NPM1上调乳腺癌中PD-L1的表达。

Hypoxia upregulates the expression of PD-L1 via NPM1 in breast cancer.

作者信息

Yu Yihui, Sun Ran, Hu Feiyun, Ding Zite, Li Xin, Han Jiyuan, Liang Leiting, Wang Tian, Xi Guifu, Dong Xueyi, Li Yanlei, Zhao Xiulan, Zhang Danfang

机构信息

Tianjin Medical University General Hospital, Tianjin, China.

Tianjin Medical University, Tianjin, China.

出版信息

J Immunother Cancer. 2025 Jun 23;13(6):e010151. doi: 10.1136/jitc-2024-010151.

DOI:10.1136/jitc-2024-010151
PMID:40550561
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12186055/
Abstract

BACKGROUND

A hypoxic microenvironment is the most frequent characteristic in tumor microenvironment. Programmed death-ligand 1 (PD-L1) is an important molecule and therapeutic target that mediates the immune response of tumor cells. Previous studies have shown that hypoxia can lead to increased expression of Nucleophosmin 1 (NPM1) and PD-L1. However, the exact regulatory mechanisms of NPM1 and PD-L1 expression under hypoxic conditions are still poorly understood.

METHODS

The relationships among hypoxia, NPM1 and PD-L1 were explored by western blotting, immunofluorescence staining, flow cytometry and chromatin immunoprecipitation-quantitativePCR(ChIP-qPCR). Animal tumor models were established to explore the effect of NPM1 expression on tumor growth. The relationships between NPM1 and breast cancer (BC) clinical features and immune infiltration were revealed by bioinformatics analysis.

RESULTS

NPM1 mediates increased PD-L1 expression in the hypoxic microenvironment of BC. HIF-1α can increase the expression of NPM1 by activating the p-AKT pathway and binding to the NPM1 promoter. Increased expression of NPM1 can promote tumor growth and inhibit T cell infiltration. Bioinformatics analysis showed that the high expression of NPM1 was associated with poorer survival and immunosuppression in patients with BC.

CONCLUSIONS

The hypoxic microenvironment promotes PD-L1 expression via NPM1 in BC, which may be further associated with the inhibition of tumor immunity. NPM1 may serve as a potential target for modulating PD-L1 immunotherapy.

摘要

背景

缺氧微环境是肿瘤微环境中最常见的特征。程序性死亡配体1(PD-L1)是介导肿瘤细胞免疫反应的重要分子和治疗靶点。先前的研究表明,缺氧可导致核磷蛋白1(NPM1)和PD-L1表达增加。然而,在缺氧条件下NPM1和PD-L1表达的确切调控机制仍知之甚少。

方法

通过蛋白质免疫印迹法、免疫荧光染色、流式细胞术和染色质免疫沉淀-定量聚合酶链反应(ChIP-qPCR)探讨缺氧、NPM1和PD-L1之间的关系。建立动物肿瘤模型以探讨NPM1表达对肿瘤生长的影响。通过生物信息学分析揭示NPM1与乳腺癌(BC)临床特征及免疫浸润之间的关系。

结果

NPM1介导BC缺氧微环境中PD-L1表达增加。缺氧诱导因子-1α(HIF-1α)可通过激活p-AKT通路并结合NPM1启动子来增加NPM1的表达。NPM1表达增加可促进肿瘤生长并抑制T细胞浸润。生物信息学分析表明,NPM1高表达与BC患者较差的生存率和免疫抑制相关。

结论

缺氧微环境通过NPM1促进BC中PD-L1的表达,这可能进一步与肿瘤免疫抑制相关。NPM1可能作为调节PD-L1免疫治疗的潜在靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7966/12186055/4cf10aa85b07/jitc-13-6-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7966/12186055/64f3d8c48372/jitc-13-6-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7966/12186055/569bb2a762f0/jitc-13-6-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7966/12186055/675bcfbee945/jitc-13-6-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7966/12186055/d6d7ae195221/jitc-13-6-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7966/12186055/500d05be4e72/jitc-13-6-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7966/12186055/4df7791949e1/jitc-13-6-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7966/12186055/8e9f9ec629cb/jitc-13-6-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7966/12186055/113e0530515b/jitc-13-6-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7966/12186055/4cf10aa85b07/jitc-13-6-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7966/12186055/64f3d8c48372/jitc-13-6-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7966/12186055/569bb2a762f0/jitc-13-6-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7966/12186055/675bcfbee945/jitc-13-6-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7966/12186055/d6d7ae195221/jitc-13-6-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7966/12186055/500d05be4e72/jitc-13-6-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7966/12186055/4df7791949e1/jitc-13-6-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7966/12186055/8e9f9ec629cb/jitc-13-6-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7966/12186055/113e0530515b/jitc-13-6-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7966/12186055/4cf10aa85b07/jitc-13-6-g009.jpg

相似文献

1
Hypoxia upregulates the expression of PD-L1 via NPM1 in breast cancer.缺氧通过NPM1上调乳腺癌中PD-L1的表达。
J Immunother Cancer. 2025 Jun 23;13(6):e010151. doi: 10.1136/jitc-2024-010151.
2
5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.5-氟尿嘧啶上调胃肠道癌中细胞表面 B7-H1(PD-L1)的表达。
J Immunother Cancer. 2016 Oct 18;4:65. doi: 10.1186/s40425-016-0163-8. eCollection 2016.
3
Co-delivery of axitinib and PD-L1 siRNA for the synergism of vascular normalization and immune checkpoint inhibition to boost anticancer immunity.阿昔替尼与程序性死亡受体配体1(PD-L1)小干扰RNA(siRNA)共递送,以实现血管正常化与免疫检查点抑制的协同作用,增强抗癌免疫力。
J Nanobiotechnology. 2025 Mar 10;23(1):194. doi: 10.1186/s12951-025-03170-y.
4
PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.程序性死亡受体1配体(PD-L1)诊断测试:评分算法和测试验证指标的系统文献综述
Diagn Pathol. 2018 Feb 9;13(1):12. doi: 10.1186/s13000-018-0689-9.
5
An immune activator encapsulating PD-L1 siRNA for augmented immune checkpoint blockade immunotherapy through Zn overload triggered pyroptosis.一种包裹程序性死亡受体配体1(PD-L1)小干扰RNA(siRNA)的免疫激活剂,通过锌过载引发细胞焦亡增强免疫检查点阻断免疫疗法。
J Nanobiotechnology. 2025 Jun 16;23(1):447. doi: 10.1186/s12951-025-03521-9.
6
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.比较 PD-1/PD-L1 联合疗法在晚期 NSCLC 一线治疗中的疗效和安全性:一项更新的系统评价和网络荟萃分析。
Clin Transl Oncol. 2024 Oct;26(10):2488-2502. doi: 10.1007/s12094-024-03442-3. Epub 2024 Apr 16.
7
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
8
Risk scoring model for lung adenocarcinoma based on PD-L1 related signature reveals prognostic predictability and correlation with tumor immune microenvironment genes was constructed.构建了基于PD-L1相关特征的肺腺癌风险评分模型,该模型揭示了预后预测能力以及与肿瘤免疫微环境基因的相关性。
Front Immunol. 2025 Jun 11;16:1601982. doi: 10.3389/fimmu.2025.1601982. eCollection 2025.
9
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.晚期 NSCLC 中 PD-L1 的表达:系统文献回顾对风险分层和治疗选择的启示。
Lung Cancer. 2017 Oct;112:200-215. doi: 10.1016/j.lungcan.2017.08.005. Epub 2017 Aug 10.
10
PARP-1 as a novel target in endocrine-resistant breast cancer.聚(ADP-核糖)聚合酶-1作为内分泌抵抗性乳腺癌的新靶点。
J Exp Clin Cancer Res. 2025 Jun 16;44(1):175. doi: 10.1186/s13046-025-03441-4.

引用本文的文献

1
Letter to the editor: LSD1 as an upstream epigenetic regulator of NPM1-PD-L1 axis in hypoxia-driven immune evasion in breast cancer.致编辑的信:在乳腺癌缺氧驱动的免疫逃逸中, LSD1作为NPM1-PD-L1轴的上游表观遗传调节因子
J Immunother Cancer. 2025 Jul 25;13(7):e013071. doi: 10.1136/jitc-2025-013071.

本文引用的文献

1
NPM1 inhibits tumoral antigen presentation to promote immune evasion and tumor progression.NPM1 抑制肿瘤抗原呈递,促进免疫逃逸和肿瘤进展。
J Hematol Oncol. 2024 Oct 14;17(1):97. doi: 10.1186/s13045-024-01618-6.
2
The relevance between hypoxia-dependent spatial transcriptomics and the prognosis and efficacy of immunotherapy in claudin-low breast cancer.缺氧依赖的空间转录组学与 Claudin-low 型乳腺癌的预后和免疫治疗疗效的相关性。
Front Immunol. 2023 Jan 4;13:1042835. doi: 10.3389/fimmu.2022.1042835. eCollection 2022.
3
Hub genes associated with immune cell infiltration in breast cancer, identified through bioinformatic analyses of multiple datasets.
通过对多个数据集的生物信息学分析鉴定出与乳腺癌免疫细胞浸润相关的枢纽基因。
Cancer Biol Med. 2022 Jul 13;19(9):1352-74. doi: 10.20892/j.issn.2095-3941.2021.0586.
4
Immunology and immunotherapy in breast cancer.乳腺癌中的免疫学与免疫疗法
Cancer Biol Med. 2022 Jun 9;19(5):609-18. doi: 10.20892/j.issn.2095-3941.2021.0597.
5
and mutations are associated with distinct blast immunophenotype in acute myeloid leukemia.并且突变与急性髓系白血病中的独特原始细胞免疫表型相关。
Oncoimmunology. 2022 May 6;11(1):2073050. doi: 10.1080/2162402X.2022.2073050. eCollection 2022.
6
NPM1 is a Novel Therapeutic Target and Prognostic Biomarker for Ewing Sarcoma.NPM1是尤因肉瘤的新型治疗靶点和预后生物标志物。
Front Genet. 2021 Nov 26;12:771253. doi: 10.3389/fgene.2021.771253. eCollection 2021.
7
Tumour-derived small extracellular vesicles suppress CD8+ T cell immune function by inhibiting SLC6A8-mediated creatine import in NPM1-mutated acute myeloid leukaemia.肿瘤来源的小细胞外囊泡通过抑制 NPM1 突变型急性髓系白血病中 SLC6A8 介导的肌酸摄取来抑制 CD8+ T 细胞免疫功能。
J Extracell Vesicles. 2021 Nov;10(13):e12168. doi: 10.1002/jev2.12168.
8
Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies.重建乳腺癌免疫监测:分子病理生理学和当前免疫治疗策略。
Int J Mol Sci. 2021 Nov 6;22(21):12015. doi: 10.3390/ijms222112015.
9
ERK signaling controls productive HIF-1 binding to chromatin and cancer cell adaptation to hypoxia through HIF-1α interaction with NPM1.ERK 信号通路通过 HIF-1α 与 NPM1 的相互作用控制 HIF-1 与染色质的有效结合,并控制癌细胞对低氧的适应。
Mol Oncol. 2021 Dec;15(12):3468-3489. doi: 10.1002/1878-0261.13080. Epub 2021 Sep 9.
10
Hypoxia and the Tumor Microenvironment.缺氧与肿瘤微环境。
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211036304. doi: 10.1177/15330338211036304.